<DOC>
	<DOC>NCT00397956</DOC>
	<brief_summary>To collect clinical response data with the use of ertapenem in community acquired sepsis.</brief_summary>
	<brief_title>To Evaluate the Treatment Effect of an Anti-Infective Agent for Complicated Infections (0826-053)</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Male or female patients, 18 years of age or older Patients present with at least two of the following signs and symptom: fever (temperature&gt; 38c or &lt; 36c) heart rate &gt; 90 beats/min) respiratory rate&gt; 20 breaths/min) high white blood cell count &gt; 12,000/ul or &gt;10% bands) Patient has a history of allergy or hypersensitivity (anaphylaxis) or serious adverse reaction to ertapenem or any carbapenem Patient has a poor chance of survival for more than 14 days. Patient has an apache ii score &gt; 15 (see attachment 3. Patient has an infection caused by pathogens resistant to ertapenem The patient requires antibiotics other than ertapenem (such as: glycopeptides, macrolides or antifungal agents)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>